Director/PDMR Shareholding
Updated : 10:02
Medica Group PLC
Director / PDMR Transaction and Shareholding
Medica Group PLC (LSE: MGP, "Medica" or the "Company"), has received notification from Dr Stuart Quin, Chief Executive Officer, that on 1 November 2021 he transferred a total of 26,546 ordinary shares of 0.2p in the Company ("Shares") to his spouse, Mallika Kaviratne, for nil consideration.
Following this transaction, there has been no change in the number of shares in which Stuart Quin has an interest.
The Notification of Dealing Forms can be found below.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and set out more details of the transactions.
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name | Stuart Quin | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Medica Group PLC | ||||
b)
| LEI
| 213800B8XE5FUSZF5Z16 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 0.2p
GB00BYV24996 | ||||
|
| |||||
b)
| Nature of the transaction
| Transfer of Ordinary Shares to Mallika Kaviratne | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information - Aggrated volume - Price
|
26,546 N/A
| ||||
e)
| Date of the transaction
| 1 November 2021 | ||||
f)
| Place of the transaction
| Outside a trading venue | ||||
For further information, please contact:
Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer
| +44 (0)33 33 111 222
|
FTI Consulting Victoria Foster Mitchell Sam Purewal | +44 (0)20 3727 1000 |
Investec Bank plc (Joint Broker) Sara Hale Daniel Adams Virginia Bull
| +44 (0)20 7597 5970 |
Liberum (Joint Broker) Bidhi Bhoma Richard Lindley Euan Brown | +44 (0)20 3100 2000 |
About Medica Group PLC
Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.
Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.
The Company currently offers two primary services to hospital radiology departments:
· NightHawk - urgent reporting service
· Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.
These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.
Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.
For more information please visit: www.medicagroupplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.